News Board

Franklin BSP Realty Trust told investors the dividend was solid. $0.355 cents a quarter. Presented as sustainable. Supported by confidence in future coverage. But behind the scenes, the math was not adding up. On November 5, 2024, executives admitted earnings were not covering the dividend. Still, they said they were “confident” in its long term...Read more

Snowflake Inc. told investors the growth story was still intact. Consumption was stabilizing. $10 billion in product revenue by 2029 was still the goal. But behind the scenes, cracks were forming. On June 27, 2023, executives assured investors usage was “back where we’d expect it to be.” Through August and November, they repeated that consumption...Read more

Navan, Inc. promised investors rapid growth. 33% percent revenue growth. 32% booking growth. A platform built for customers of all sizes across industries. Then came the IPO in October 2025. Shares priced at $25. Nearly $920 million raised. Confidence was high. But behind the scenes, something wasn’t in the spotlight. On October 31, the same...Read more

Lakeland Industries told investors its acquisition strategy was small, strategic, and quick. Pacific Helmets. Jolly Boots. Global expansion. Strong guidance. Big expectations. But behind the scenes, those shiny new acquisitions were struggling. On September 4, 2024, Lakeland missed revenue. Executives blamed shipment delays at Jolly. The stock slipped. In April 2025, things got worse. Earnings...Read more

Zynex told investors it was changing pain management. Record orders. Record revenue. The Company touted profitability and record results. But behind the scenes, something else was growing. Starting in 2021, executives blamed “strong order flow” and sales productivity for soaring numbers. They said doctors needed their non opioid devices. They said demand was real. According...Read more

Corcept told investors relacorilant was the future. A safer, next generation treatment for Cushing’s syndrome.   They said the data was powerful. Approval was coming. No impediments to approval. On October 30, 2024, executives said their Phase Three trials cleared the path for an FDA application.   By December 30, 2024, they announced the application...Read more

NuScale told investors its small modular reactors were the future of clean energy. A game changer. A faster, safer path to nuclear power. And they had the perfect partner to make it happen. Starting in May 2025, NuScale pointed to ENTRA1 as its exclusive global commercialization partner. Executives called it a one stop shop. A...Read more

Enphase told investors it could control its destiny. New products. Inventory discipline. Optimistic commentary about demand despite tax credit changes. It sounded steady. Strategic. Safe. On April 22,2025, Enphase emphasized discipline in managing channel inventory and introducing new products. In July, after Congress moved up the expiration of the 25D solar tax credit, executives painted...Read more

On March 26, 2026, two Co-Lead Plaintiffs were appointed in the class action lawsuit captioned Diamond v. Firefly Aerospace Inc., et al., 1:25-cv-01812-DAE. Senior United States District Judge in the Western District of Texas, David Alan Ezra, signed the order that also approved Levi & Korsinsky, LLP and Robbins Geller Rudman & Dowd LLP as...Read more

Ostin Technology told investors it was building a high growth display business. A Nasdaq listed company. New capital. Big opportunity. According to a criminal indictment, prosecutors say it was something else entirely. A carefully orchestrated pump and dump. In April 2025, Ostin closed a $5 million stock offering at a steep discount. Weeks later, insiders...Read more

PayPal Holdings, Inc. told investors it was about to win checkout. Big growth. High single digits. Even double digit earnings expansion by 2027. Executives said their branded checkout revamp was working. New products. Better conversion. Strong U.S. momentum. But here is what investors did not hear. On February 25, 2025, leadership laid out bold targets...Read more

Regenxbio told investors it was on the brink of a breakthrough. A one time gene therapy. Encouraging biomarker data. No serious safety issues. It sounded like hope for families and a huge opportunity for shareholders. Starting in February 2022, the company highlighted positive early results for RGX-111, calling it well tolerated with no drug related...Read more

uniQure told investors it was on the brink of something historic. A gene therapy that could actually slow Huntington’s disease. FDA aligned. Data locked in. Approval on track for early 2026. Then everything unraveled. On September 24, 2025, uniQure announced its AMT-130 trial hit its main goal. They claimed a 75% slowing of disease progression....Read more

Kyndryl told investors its financial controls were solid. Effective. Remediated. Nothing to worry about. But behind the scenes, the numbers were not adding up. Starting in August 2024, Kyndryl filed quarterly reports admitting to limited IT control issues, while assuring investors there were no material misstatements. In May 2025, the company went even further. It...Read more

Inovio told investors it was on the verge of history. A breakthrough DNA medicine. Accelerated FDA approval. A fast track to becoming a full commercial company. It sounded like a turning point. Starting in October 2023, Inovio said the FDA agreed its Phase I/II data could support accelerated approval for INO-3107. In January 2024, executives...Read more